

**PREPARATORY COMMITTEE
FOR THE
WORLD TRADE ORGANIZATION**

RESTRICTED

G/RS/25

15 December 1994

(94-2795)

Original: English

**RECTIFICATIONS AND MODIFICATIONS TO SCHEDULES
ANNEXED TO THE MARRAKESH PROTOCOL**

Schedule V - Canada

The following communication, dated 7 December 1994, has been received from the Permanent Mission of Canada.

Please find attached a technical corrigendum¹ to Schedule V - Canada in respect of the arrangement to eliminate duties on pharmaceutical products. This corrigendum does not alter Canada's MTN commitments.

If no objection is notified to the Secretariat within 30 days from the date of this document, the rectifications to Schedule V - Canada will be deemed to be approved and will be formally issued as a Procès-Verbal.

¹English only

CORRIGENDUM TO SCHEDULE V - CANADA
ANNEX D - PHARMACEUTICAL PRODUCTS
(English Version)

Canada is submitting the following changes to the English version of Schedule V, Annex D. Most of these changes are technical in nature while others reflect corrections already agreed by the Contracting Parties. The changes do not alter Canada's commitment to eliminate duties on any of the pharmaceutical products specified in its schedule which was attached to the Marrakesh Protocol.

ANNEX I:

1. The following line is deleted:

290611	2216-51-5	levomenthol
--------	-----------	-------------

2. The following INNs were listed twice in Annex I with two CAS numbers. The duplicates with the incorrect CAS RN are removed as follows:

291570	555-44-2	tripalmitin
292250	407-41-0	dexfosfoserine
292250	96346-61-1	onapristone
293090	5667-98-1	aldesulfone sodium
293390	84812-85-1	tazadolene
293410	68247-85-8	peplomycin
293490	100599-27-7	tenidap

3. The words "excluding monosodium glutamate" should be inserted after "glutamic acid (INN)" as follows:

292242	56-86-0	glutamic acid (INN) excluding monosodium glutamate
--------	---------	--

4. The following (ISO) abbreviations are replaced by the appropriate (INN):

291430	82-66-6	<i>diphenadione (INN)</i> replaces <i>diphacinone (ISO)</i>
291900	470-90-6	<i>clofenvinfos (INN)</i> replaces <i>chlorfenvinphos (ISO)</i>
292010	2104-96-3	<i>bromofos (INN)</i> replaces <i>bromophos (ISO)</i>
292010	299-84-3	<i>fenclofos (INN)</i> replaces <i>fenchlorphos (ISO)</i>
292429	63-25-2	<i>carbaril (INN)</i> replaces <i>carbaryl (ISO)</i>
293090	786-19-6	<i>carbofenotion (INN)</i> replaces <i>carbophenothion (ISO)</i>
293090	3383-96-8	<i>temefos (INN)</i> replaces <i>temephos (ISO)</i>
293100	52-68-6	<i>metrifonate (INN)</i> replaces <i>trichlorfon (ISO)</i>
293229	56-72-4	<i>coumafos (INN)</i> replaces <i>coumaphos (ISO)</i>
293290	78-34-2	<i>dioxation (INN)</i> replaces <i>dioxathion (ISO)</i>
293359	333-41-5	<i>dimpylate (INN)</i> replaces <i>diazinon (ISO)</i>
293410	148-79-8	<i>tiabendazole (INN)</i> replaces <i>thiabendazole (ISO)</i>

5. The following spelling corrections are made in accordance with **L/7430/Add.4** of August 3, 1994:

292229	1518-86-1	<i>hydroxyamfetamine</i> replaces <i>hydroxyamphetamine</i>
292250	85750-39-6	<i>etilefrine pivalate</i> replaces <i>etilefrine privalate</i>
293490	118812-69-4	<i>ularitide</i> replaces <i>ulartitude</i>

ANNEX II:

1. "SODIUM" is added to the list following "SALICYLOYLACETATE" in accordance with **L/7430/Add.4** of 3 August 1994.

2. "(PIVALOYLOXY)METHYL HYDROCHLORIDE" is added to the list following "(PIVALOYLOXY)METHYL" as the former is a synonym for "PIVOXIL HYDROCHLORIDE" which is already listed in Annex II.

3. The following WHO radicals or groups which were previously missing from Annex II are each added to the list in alphabetical order:

ACETURATE	DEANIL	METEMBONATE
ACISTRATE	DECIL	MOFETIL
ACOXIL	DIBUDINATE	OCTIL
AMSONATE	DIBUNATE	OLAMINE
BEZOMIL	DIGOLIL	OXOGLURATE
BUCICLATE	DIOLAMINE	PIVOXETIL
BUNAPSILATE	DOCOSIL	PROXETIL
BUTEPRATE	DOFOSFATE	STEAGLATE
CARBESILATE	ERBUMINE	TENOATE
CICLOTATE	ETABONATE	TEPROSILATE
CIPIONATE	FARNESIL	TOFESILATE
CLOSILATE	FENDIZOATE	TRICLOFENATE
CROBEFATE	HIBENZATE	TRIFLUTATE
CROMACATE	HYCLATE	TROLAMINE
CROMESILATE	LAURILSULFATE	TROXUNDATE
DAPROPATE	MEGALLATE	XINAFOATE

4. The following items are replaced to correct spelling or to make minor modifications such as the addition or deletion of spaces:

ALLYLBROMIDE replaces ALLYL BROMIDE
 ALLYLIODIDE replaces ALLYL IODIDE
 BENZYL BROMIDE replaces BENZYL BROMIDE
 BENZYLIODIDE replaces BENZYL IODIDE
 BIS (HYDROGEN MALATE) replaces BIS (HYDROGEN) MALATE
 BIS (HYDROGEN MALEATE) replaces BIS (HYDROGEN) MALEATE
 BIS (HYDROGEN MALONATE) replaces BIS (HYDROGEN) MALONATE
 CAMPHOR-10-SULPHONATE replaces CAMPHOR-10-SUPHONATE
 CYCLOHEXANEPROPIONATE replaces CYCLOHEXANPROPIONATE

ETHYL IODIDE replaces ETHYL IODIDE
1,5-NAPHTHALENEDISULFONATE replaces 1,5-NAPHTHALENESULFONATE

PROPIONATEDODECYL SULPHATE replaces PROPIONATE DODECYL
SULPHATE

SODIUM HYDROGEN PHOSPHATE replaces SODIUM HYDROGEN
PHOSPHATESODIUM

SODIUM METHANESULPHONATE replaces METHANESULPHONATE
SUCCINYL replaces SUCCINIL

5. The following are re-arranged in the alphabetical listing as the "N" should not be taken into account for the alphabetical order:

N-CYCLOHEXYLSULPHAMATE is moved to follow CYCLOHEXYLPROPIONATE
N-OXIDE HYDROCHLORIDE is moved to follow OXIDE

6. The following are deleted from the list as they are duplicates and triplicates with minor spelling variations:

BESYLATE	ISETHIONATE
tert-BUTYL ACETATE	MESYLATE
tertiary BUTYL ACETATE	METHYLSULFATE
tert-BUTYL ESTER	METHYLSUPHATE
tertiary BUTYL ESTER	NAPADISYLATE
CAMSYLATE	NAPSYLATE
DECANOATE	THEOCLATE
ENANTHATE	
ESYLATE	

ANNEX III:

1. The following items are deleted:

2907.29 DIETHYLSTILBESTROL DIETHYLSTILBESTROL DIFUROATE 2932.19
549-40-6

This item corresponds to Furostilbestrol (INN) which is already included in Annex I.

2933.39 HALOPERIDOL HALOPERIDOL DECANOATE 2933.90 74050-97-8
As the correct HS classification of HALOPERIDOL DECANOATE is 2933.39, it is in the same subheading as the active ingredient and does need to be listed in Annex III.

2934.30 PROMETHAZINE PROMETHAZINE TEOCLATE 2939.50 17693-51-5
PROMETHAZINE TEOCLATE is an INN in its own right and is already included in Annex I.

2. The following items are replaced to correct spelling or for the addition of spaces in accordance with **L/7430/Add.4** of 3 August 1994:

2909.49 886-74-8 replaces 2909.49 886-74-8	CHLORPHENESIN	CHLORPHENESIN CARBAMATE	2924.29
	CHORPHENESIN	CHORPHENESIN CARBAMATE	2924.29
2918.90 replaces 2918.90	ENOXOLONE	ENOXOLONE DIHYDROGEN PHOSPHATE	2919.00 18416-35-8
	ENOXOLONE	ENOXOLONE DIHYDROGENPHOSPHATE	2919.00 18416-35-8

3. The following corrections of CAS RN are made in accordance with **L/7430/Add.4** of 3 August 1994:

CAS RN 742-92-2 is replaced by 74203-92-2; and
CAS RN 13931-76 is replaced by 13931-75-4

ANNEX IV:

1. The following are amended to reflect the proper HS subheading:

2918.50 becomes 2918.90	30131-16-9	4-(Phenylbutoxy) benzoic acid
	30131-16-9	4-(Phenylbutoxy) benzoic acid
2922.19 becomes 2922.29	120-20-7	2-(3,4-Dimethoxyphenyl)ethylamine
	120-20-7	2-(3,4-Dimethoxyphenyl)ethylamine
2922.50 becomes 2922.29	55174-61-3	Benzene-ethanamine-3,4-dimethoxy-betamethyl
	55174-61-3	Benzene-ethanamine-3,4-dimethoxy-betamethyl
2932.29 becomes 2933.29	24155-42-8	alpha-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol
	24155-42-8	alpha-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol
2932.59 becomes 2932.29	298-81-7	8-Methoxypsoralen
	298-81-7	8-Methoxypsoralen
2932.90 becomes 2932.19	37743-18-3	N-[Dihydro-3,3-diphenyl-2(3H)-furanlylidene]-N-methylmethanaminium bromide
	37743-18-3	N-[Dihydro-3,3-diphenyl-2(3H)-furanlylidene]-N-methylmethanaminium bromide
2933.29 becomes	103094-30-0	3-Ethyl-5-methyl-4-(2-chlorophenyl)-1,4-dihydro-2-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl) ethoxy (methyl)-6-methyl-3,5-pyridine dicarboxylate

2933.39	103094-30-0	3-Ethyl-5-methyl-4-(2-chlorophenyl)-1,4-dihydro-2-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl) ethoxy (methyl)-6-methyl-3,5-pyridine dicarboxylate
2933.39 becomes 2933.29	83857-96-9 83857-96-9	1H-Imidazole-4-carboxaldehyde, 2-butyl-5-chloro- 1H-Imidazole-4-carboxaldehyde, 2-butyl-5-chloro-
2933.40 becomes 2933.59	7597-60-6 7597-60-6	1,3-Dimethyl-4-amino-5-formylaminouracil 1,3-Dimethyl-4-amino-5-formylaminouracil
2933.90 becomes 2933.39	57988-58-6 57988-58-6	4-(4-Bromophenyl)-4-piperidinol 4-(4-Bromophenyl)-4-piperidinol
2934.90 becomes 2933.90	9585-13-5 9585-13-5	5-Ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one 5-Ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one
2934.90 becomes 2933.90	114873-37-9 114873-37-9	1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid
2934.90 becomes 2933.90	66242-82-8 66242-82-8	2,5-Dihydro-5-thioxo-1H-tetrazole-1-methanesulphonic acid, disodium salt 2,5-Dihydro-5-thioxo-1H-tetrazole-1-methanesulphonic acid, disodium salt

2. As the following items correspond to INNs included in Annex I, they are deleted from Annex IV:

2924.29	29122-68-7	2-[4-(2-Hydroxy-3-isopropyl aminopropoxy)phenyl] acetamide corresponds to atenolol (INN)
2932.19	66357-35-5	N-[2-((5-((Dimethylamino)methyl)-2-furanylmethyl)thio)-ethyl]-N-methyl-2-nitro-1,1-ethenediamine corresponds to ranitidine (INN)
2933.39	115-46-8	alpha, alpha-Diphenyl-4-piperidinemethanol hydrochloride corresponds to azacyclonol (INN)
2933.59	98079-51-7	1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid corresponds to lomefloxacin (INN)
2933.79	105431-72-9	2H-Indol-2-one, 1,3-dihydro-1-phenyl-3,3-bis (4-pyridinylmethyl) corresponds to linopirdine (INN)

2933.90 91441-48-4 Anthra[1,9-cd] pyrazol-6(2H)-one,7,10-dihydroxy-2 (2-[(2-hydroxyethyl)amino]ethyl)-5-[(2-(methylamino)ethyl)amino] corresponds to teloxantrone (INN)

2934.90 53910-25-1 (R)-3-(2-Deoxy-beta-D-erythropentofuranosyl)-3,4,7,8-tetrahydro-imidazo-(4,5)(1,3)diazepin-8-ol corresponds to pentostatin (INN)

2934.90 69655-05-6 2',3'-Dideoxyinosine corresponds to didanosine (INN)

2934.90 3056-17-5 3'-Deoxy-2',3'-didehydrothymidine corresponds to stavudine (INN)

3. The CAS No indicated below replaces the designation "NA" on the following items:

2926.90 151338-11-3 3-Cyano-N-(1,1-dimethylethyl)-androsta-3,5-diene-17 beta-carboxamide

2931.00 123599-78-0 [(2-Methyl-1)-1-oxyl propoxy](propoxy)-(4-phenylbutyl 1)-phosphinyl] acetate